000			02178 a2200625 4500
005			20250517101407.0
264		0	_c20170829
008			201708s 0 0 eng d
022			_a1365-2036
024	7		_a10.1111/apt.13696 _2doi
040			_aNLM _beng _cNLM
100	1		_aBackus, L I
245	0	0	_aComparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice. _h[electronic resource]
260			_bAlimentary pharmacology & therapeutics _c08 2016
300			_a400-10 p. _bdigital
500			_aPublication Type: Comparative Study; Journal Article; Observational Study
650	0	4	_a2-Naphthylamine
650	0	4	_aAdult
650	0	4	_aBlack or African American
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAnilides _xtherapeutic use
650	0	4	_aAntiviral Agents _xtherapeutic use
650	0	4	_aBenzimidazoles _xtherapeutic use
650	0	4	_aCarbamates _xtherapeutic use
650	0	4	_aCyclopropanes
650	0	4	_aDrug Combinations
650	0	4	_aDrug Therapy, Combination
650	0	4	_aFemale
650	0	4	_aFluorenes _xtherapeutic use
650	0	4	_aGenotype
650	0	4	_aHepacivirus _xgenetics
650	0	4	_aHepatitis C, Chronic _xblood
650	0	4	_aHumans
650	0	4	_aLactams, Macrocyclic
650	0	4	_aMacrocyclic Compounds _xtherapeutic use
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aProline _xanalogs & derivatives
650	0	4	_aRNA, Viral _xblood
650	0	4	_aRibavirin _xtherapeutic use
650	0	4	_aRitonavir _xtherapeutic use
650	0	4	_aSofosbuvir _xtherapeutic use
650	0	4	_aSulfonamides _xtherapeutic use
650	0	4	_aSustained Virologic Response
650	0	4	_aUracil _xanalogs & derivatives
650	0	4	_aValine
650	0	4	_aYoung Adult
700	1		_aBelperio, P S
700	1		_aShahoumian, T A
700	1		_aLoomis, T P
700	1		_aMole, L A
773	0		_tAlimentary pharmacology & therapeutics _gvol. 44 _gno. 4 _gp. 400-10
856	4	0	_uhttps://doi.org/10.1111/apt.13696 _zAvailable from publisher's website
999			_c26116003 _d26116003